Cost benefit of early diagnosis of colorectal cancer.
In most Western countries, colorectal cancer is an important disease in terms of morbidity and mortality. As it has a premalignant asymptomatic stage in the form of benign adenomas that might be detected by screening, and as screening leads to detection of colorectal cancer at an earlier stage, there is potential for improved and better quality survival. Most cost-effective analyses rank the various screening strategies at less than an accepted benchmark value of approximately $40,000 per added year of life. Periodic colorectal screening is therefore a cost-effective intervention and the Office of Technology Assessment of the Congress of the United States has concluded that colorectal cancer screening in average-risk adults beginning at age 50 is a relatively good investment for society. Flexible sigmoidoscopy and double contrast barium enema are the most cost-effective strategies but they both require colonoscopy if a lesion is identified. Colonoscopy at 10-yearly intervals is of comparable cost to flexible sigmoidoscopy every 5 years and less costly than FSIG every 3 years. Combination strategies, using faecal occult blood testing with periodic flexible sigmoidoscopy or double contrast barium enema are as costly as colonoscopy. The choice of screening strategies needs to be tailored to the individual, and a process of community education is an essential prerequisite to the success of any programme.
Bolin
T D
TD
Gastrointestinal Unit, Prince of Wales Hospital, Randwick NSW, Sydney, Australia.
D001466:Barium Sulfate; D003113:Colonoscopy / Q000191:economics*; D015179:Colorectal Neoplasms / Q000191:economics / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D004733:Enema; D006801:Humans; D008403:Mass Screening / Q000191:economics*
D001466:Barium Sulfate